Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells

BACKGROUND: Since treatment of neuroblastoma (NB) with anti-GD2 monoclonal antibodies provides a survival benefit in children with minimal residual disease and our preclinical study shows that anti-CD3 x anti-GD2 bispecific antibody (GD2Bi) armed T cells (GD2BATs) were highly cytotoxic to GD2+ cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Yankelevich, Maxim, Thakur, Archana, Modak, Shakeel, Chu, Roland, Taub, Jeffrey, Martin, Alissa, Schalk, Dana L., Schienshang, Amy, Whitaker, Sara, Rea, Katie, Lee, Daniel W., Liu, Qin, Shields, Anthony, Cheung, Nai-Kong, Lum, Lawrence G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659559/
https://www.ncbi.nlm.nih.gov/pubmed/37986911
http://dx.doi.org/10.21203/rs.3.rs-3570311/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659559/
https://www.ncbi.nlm.nih.gov/pubmed/37986911
http://dx.doi.org/10.21203/rs.3.rs-3570311/v1

Ejemplares similares